Notice Number: NOT-AI-05-045
Release Date: June 17, 2005
Receipt Date: September 1, 2005
The Project BioShield Act of 2004, enacted on July 21, 2004, authorizes the Secretary, Department of Health and Human Services (DHHS), through the program carried out by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), to expedite peer review of grants, contracts, and cooperative agreements to perform, administer, or support research and development of countermeasures determined by the Secretary to be a priority to treat, identify, or prevent harm from any biological, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security, or adverse health consequences that may arise from using such a countermeasure. Consistent with this authority, the NIAID is announcing a new grant initiative focused on assay development for influenza therapeutics.
This notice provides information regarding the overall objectives and key features of the new NIAID initiative. More detailed information and instructions on project eligibility, application requirements, and application submission and award procedures is provided at http://www.niaid.nih.gov/biodefense/bioshield.htm.
In FY 2006, the NIAID intends to commit up to $10 million to support research projects focused on the development of assays that are suitable for screening and development of influenza therapeutics. Actual production of chemical entities or other therapeutic candidates or screening of these candidates for biological activity or biomolecular interaction will not be supported by this initiative. Support will be provided for up to $1.5 million in total costs per award for a project period of up to eighteen (18) months.
Potential applicants MUST first obtain NIAID approval to submit an application by providing a summary of their proposed research to the NIAID staff contact listed below. This approval request must be prepared using page 2 of the PHS 398 (https://grants.nih.gov/grants/funding/phs398/phs398.html), must contain a cover letter providing contact information, and must be provided by email no later than August 18, 2005. Requests submitted past this deadline will not be considered. Once written permission to submit an application has been granted, this written permission must be included with the application.
A letter application of no more than ten (10) pages must be submitted by September 1, 2005 and must provide the rationale for the proposed project, preliminary data including evidence of target validation, and the research plan. In addition to this letter, applications must contain: the PHS 398 face page, the PHS 398 page 2, the PHS 398 budget pages 4 and 5; documentation of NIAID approval to accept the application for review; and biographical sketches. An expedited review process will provide for peer review of applications approximately two (2) months after receipt. Awards will be expedited to the fullest extent possible. Award dates will be determined, in part, by the submission of additional documentation and assurances by the successful applicants to meet funding, policy and regulatory requirements.
Inquiries regarding this notice may be directed to:
Dr. Karen Lacourciere
Division of Microbiology and Infectious Diseases
National Institute for Allergy and Infectious Diseases
6610 Rockledge Dr, Room 5032
Bethesda, MD 20817
Mail Stop 6604
Detailed information and instructions on project eligibility, application requirements, and application submission and award procedures is provided at http://www.niaid.nih.gov/biodefense/bioshield.htm.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.